MediWound Ltd.
MDWD
NASDAQ·Healthcare·Biotechnology·Mkt cap $170.7M
$13.29
▲ +0.61%
P/E
-14.32
Mkt Cap
$170.7M
52-Wk Range
$12.52–$20.30
52-Week Range
$12.52 - $20.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary enzymatic debridement technology with clinical validation
- FDA-approved flagship product with established market presence
- Diversified pipeline reducing dependency on single product
- Specialized expertise in tissue repair and regeneration
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
NexoBrid market expansion and adoption in burn centers globally
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-6.5% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MDWD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 19, 2026
AUG 13, 2026
Reported EPS of -$0.77 vs -$0.76 consensus (-1.1% surprise). Revenue of $3.1M vs $2.6M expected (+19.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.1%
Revenue trend · last 8Q
—
+9%
-20%
+13%
+25%
-68%
-63%
-46%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.5M
$2.0M
$1.4M
$2.0M
$1.9M
$649.3K
$513.0K
$3.1M
Margins · last 8Q
Gross
10.9%
Operating
—
Profit
-239.1%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 14, 2026
vs Industry
How MDWD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related